MedTrace Logo

Insulin Resistance in Women With Prolactinoma

NCT00481299 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2004

Last updated 2007-06-01

No results posted yet for this study

Summary

Prolactin is suggested to influence insulin resistance, but scarce data is available on the metabolic profile of patients with prolactinoma.

The purpose of the protocol was to evaluate cardiovascular disease risk factors in women with prolactinoma treated with dopamine agonists and to study the influence of disease control and anthropometry on their metabolic profile.

Conditions

Sponsors & Collaborators

  • Universidade Federal do Rio de Janeiro

    lead OTHER

Principal Investigators

  • Erika CO Naliato, MSc · Federal University of Rio de Janeiro - Brazil

Eligibility

Min Age
18 Years
Max Age
48 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-10-31
Completion
2006-09-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00481299 on ClinicalTrials.gov